Close Menu

NEW YORK – AnPac Bio-Medical Science said on Thursday that it has signed an agreement with Keystone Capital Partners for a preferred stock investment for an aggregate purchase price of $7 million.

The Shanghai-based firm will use the funding to advance its Cancer Differentiation Analysis (CDA) technology to provide cost-effective, early detection screening and testing of 26 cancers.

According to a prospectus summary filed with the US Securities and Exchange Commission, AnPac will offer 700,000 shares at a price of $10.00 per share to Keystone.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.